Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation.
OBJECTIVE
• To determine (i) the presence of fatty acid amide hydrolase (FAAH) in the urinary bladder; (ii) whether or not endogenous fatty acid ethanolamides are synthesized by the bladder; (iii) the effects of FAAH inhibition on referred hyperalgesia associated with acute bladder inflammation in rats.


METHODS
• Immunohistochemistry and immunoblotting were performed to detect FAAH in the bladder. Acrolein (1 mM, 400 µL) was instilled into bladders of female Wistar rats to induce cystitis. Referred mechanical hyperalgesia was assessed by application of Von Frey monofilaments to the hind paws. • Animals were killed 4, 24, 48 and 72 h after acrolein instillation, and the fatty acid ethanolamide content of bladders was measured using isotope-dilution liquid chromatography/mass spectrometry. • Other rats were treated with the FAAH inhibitor URB597 (0.3 mg/kg, i.p.) after the induction of cystitis, and the mechanical sensitivity of the hind paws was determined.


RESULTS
• Immunohistochemistry and immunoblotting showed the presence of FAAH in the bladder, with greatest abundance in the urothelium. • Acrolein-induced cystitis increased fatty acid ethanolamide content (including anandamide) in the bladder in a time-dependent manner. Inhibition of FAAH diminished referred hyperalgesia associated with acute bladder inflammation.


CONCLUSIONS
• The results obtained in the present study indicate that (i) FAAH is present in the urinary bladder; (ii) fatty acid ethanolamides are increased during bladder inflammation; (iii) inhibition of FAAH could be an effective therapeutic approach for the treatment of bladder pain. • These results raise the possibility that inhibitors of enzymes responsible for metabolism of fatty acid ethanolamides could inhibit pain associated with bladder inflammation.
Merriam
Fabiola Voznika
FV
Department of Surgical Sciences, School of Veterinary Medicine, Medical College of Wisconsin, Milwaukee, WI 53706, USA.
Wang
Zun-Yi
ZY
Hillard
Cecilia J
CJ
Stuhr
Kara L
KL
Bjorling
Dale E
DE
D000581:Amidohydrolases / Q000037:antagonists & inhibitors*; D000818:Animals; D003556:Cystitis / Q000150:complications*; D005260:Female; D006930:Hyperalgesia / Q000188:drug therapy* / Q000209:etiology*; D051381:Rats; D017208:Rats, Wistar; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D000099252:Fatty Acid Amide Hydrolases
Am J Physiol Regul Integr Comp Physiol. 2008 Jul;295(1):R111-22
18448607
BJU Int. 2007 Jun;99(6):1523-9
17346276
Neuropharmacology. 2005 Jun;48(8):1154-63
15910891
Nature. 1998 Jul 16;394(6690):277-81
9685157
J Neurobiol. 2004 Oct;61(1):45-54
15362152
Nat Clin Pract Urol. 2006 Jan;3(1):45-53
16474494
J Neurochem. 2001 Sep;78(6):1415-27
11579150
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9371-6
11470906
Eur J Neurosci. 2005 Feb;21(4):1057-69
15787710
J Pharmacol Exp Ther. 2005 Apr;313(1):352-8
15579492
Anesthesiology. 2001 Mar;94(3):507-13; discussion 6A
11374613
Pain. 1998 Mar;75(1):111-119
9539680
J Urol. 2009 Apr;181(4):1932-8
19237176
J Pharmacol Exp Ther. 2006 Dec;319(3):1051-61
16997973
Urology. 2008 Nov;72(5):1174-8
18468662
Br J Pharmacol. 2001 Aug;133(8):1263-75
11498512
J Neurosci. 2004 Dec 15;24(50):11253-63
15601931
Nature. 1996 Nov 7;384(6604):83-7
8900284
J Biol Chem. 2003 Nov 7;278(45):45034-9
12949078
J Neurochem. 2003 Feb;84(3):585-91
12558978
CNS Drug Rev. 2006 Spring;12(1):21-38
16834756
Pain. 2008 Sep 30;139(1):158-167
18445509
Mol Pharmacol. 2005 Jan;67(1):15-9
15465922
Urology. 2002 May;59(5 Suppl 1):43-50
12007522
Pain. 1998 May;76(1-2):189-99
9696473
J Neurosci. 2009 Mar 25;29(12):3766-80
19321773
J Lipid Res. 2005 Feb;46(2):342-9
15576840
J Urol. 2005 Jun;173(6):1983-7
15879797